Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a <i>post-hoc</i> analysis of a randomised phase III study.

World Allergy Organ J · 2020 · PMC8461112 · PMID 34611470

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

showed a trendP = 0.051so close (0.05 < p ≤ 0.1)

AQLQ scores showed a trend of improvement in Group 1 ( P = 0.051), and improvements in Group 3 ( P < 0.001) in patients treated with omalizumab at Week 24 ( Fig. 1 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.